| # | Drug | Count |
|---|---|---|
| 0 | CAPECITABINE | 10 |
| 1 | LAPATINIB | 10 |
| 2 | BEVACIZUMAB | 9 |
| 3 | DOCETAXEL | 9 |
| 4 | DOCETAXEL ANHYDROUS | 9 |
| 5 | FULVESTRANT | 9 |
| 6 | LETROZOLE | 9 |
| 7 | LETROZOLE TABLETS | 9 |
| 8 | PACLITAXEL | 9 |
| 9 | TRASTUZUMAB | 9 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ONASEMNOGENE ABEPARVOVEC-XIOI | 3 | 0.0013 |
| 1 | VINORELBINE | 8 | 0.0011 |
| 2 | ERDAFITINIB | 1 | 0.0008 |
| 3 | LAPATINIB | 10 | 0.0006 |
| 4 | PYRAZINAMIDE | 3 | 0.0003 |
| 5 | GEMTUZUMAB OZOGAMICIN | 1 | 0.0003 |
| 6 | FULVESTRANT | 9 | 0.0003 |
| 7 | DOPAMINE HYDROCHLORIDE | 1 | 0.0003 |
| 8 | RIFAMPIN | 3 | 0.0002 |
| 9 | PONATINIB HYDROCHLORIDE | 1 | 0.0002 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD33-directed Immunoconjugate [EPC] | 1 | 0.0003 |
| 1 | Estrogen Receptor Antagonist [EPC] | 9 | 0.0002 |
| 2 | Antimycobacterial [EPC] | 3 | 0.0001 |
| 3 | HER2/neu Receptor Antagonist [EPC] | 9 | 0.0001 |
| 4 | Rifamycin Antibacterial [EPC] | 3 | 0.0001 |
| 5 | Aromatase Inhibitor [EPC] | 9 | 0.0001 |
| 6 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 1 | 0.0001 |
| 7 | Asparagine-specific Enzyme [EPC] | 1 | 0.0001 |
| 8 | Microtubule Inhibitor [EPC] | 10 | 0.0001 |
| 9 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 9 | 0.0000 |